Condition: Classic Hodgkin Lymphoma · Sponsor: Sun Yat-sen University
This study is conducted to evaluate the safety and efficiency of Penpulimab combined with AVD in patients with newly- diagnosed advanced classic Hodgkin lymphoma.
This description comes directly from the study's public registry record.
Qingqing Cai, MD. PhD. · 0086-20-87342823 · caiqq@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05949931